CARLOS JIMENEZ: Open Payments
NPI 1689636987 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$560 in 26 payments from 10 companies in 2025. Trend: 2023 $877 · 2024 $761 · 2025 $560
Food & beverage: $560
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $193 |
| Amgen Inc. | 4 | $93 |
| Novo Nordisk Inc | 2 | $50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $35 |
| Exact Sciences Corporation | 1 | $33 |
| Astellas Pharma US Inc | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $28 |
Products named: AIRSUPRA, OTEZLA, BREZTRI, JARDIANCE, MOUNJARO, Cologuard Collection Kit, Veozah, REXULTI.
Industry payments across NV — which companies pay providers there.
